Dr. Reddy's Laboratories is currently trading at Rate RS 1284.45, rising by 32.30 points or 2.58% from its previous close of Rate RS 1252.15 on the BSE.

The stock opened at Rate RS 1260.00 and has touched an intraday high of Rate RS 1303.45 and a low of Rate RS 1260.00 so far. A total of 1,59,192 shares have been traded on the counter.

This BSE Group 'A' stock, with a face value of Rate RS 1, has recorded a 52-week high of Rate RS 1420.20 on 21-Aug-2024 and a 52-week low of Rate RS 1025.90 on 07-Apr-2025.

Over the past week, the stock has seen a high of Rate RS 1303.45 and a low of Rate RS 1232.55. The current market capitalization of the company stands at Rate RS 1,07,360.12 crore.

Promoter holding in Dr. Reddy's is 26.64%, while institutional investors hold 51.37% and non-institutional investors account for 10.44%.

The rally comes on the back of an announced collaboration and license agreement between Dr. Reddy's Laboratories and Alvotech to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets. Keytruda is widely used in the treatment of various cancers and recorded global sales of USD 29.5 billion in 2024.

The partnership leverages both companies’ strengths in biosimilars, aiming to accelerate development and broaden the global market reach of the biosimilar candidate. Under the agreement, both companies will jointly share development, manufacturing, and commercialization responsibilities, with each retaining rights to market the product globally, subject to certain exceptions.

Dr. Reddy's Laboratories, headquartered in Hyderabad, Telangana, is a leading multinational pharmaceutical company engaged in manufacturing and marketing a broad portfolio of pharmaceutical products in India and abroad.